A Phase 3 interventional study of Probenecid 500 Milligrams (mg) and probenecid 250 Milligrams (mg) in Infertility, Male, sponsored by University of Miami. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by University of Miami · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Infertility, Male with a site in United States — 12 open to participants now, 16 under way, 1 of them phase 3. Infertility, Male · United States.
Among the 58 studies in Infertility, Male with a site in United States, this one is the 11th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 3, reaches primary completion later than 9 of the 15 other live ones, and was the 49th registered.
283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.
Browse Infertility, Male studies →12 of the 58 studies in Infertility, Male with a site in United States are open now. Recruiting first, the newest first:
Reproductive Medicine Associates of New Jersey · Sites in United States
Men only
CellARTs Inc. · Sites in United States
Ages 18–60 · Men only · Healthy volunteers
University of Pittsburgh · Sites in United States
Men only
The Bird and Be Co Inc · Sites in United States
Ages 18–50 · Men only · Healthy volunteers
Stanford University · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Infertility, Male studies recruiting now, 17 (41%) set no upper age limit and 24 (59%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 3 · Phase 4 1
First in 2000; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 80 across 188 interventional studies indexed under Infertility, Male.
Median enrollment 58 across the 36 interventional studies, 215 across the 22 observational. Of the 35 that completed or were terminated, 17 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 58 have an industry lead sponsor. The 10 most frequent:
University of Miami is the lead sponsor of 843 studies on the registry; 166 are open to participants now.
Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.
University of Miami has 2 studies filed under Infertility, Male — fewer than ten, so there is no comparison to draw.
7 of the studies in Infertility, Male with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05903859Phase 3University of MiamiImprovement of Reproductive Function in Men With Spinal Cord Injury (SCI) | 2027-05-31 |
| NCT06566599Inception Fertility Research Institute, LLCPreimplantation Genetic Testing for Aneuploidy (PGT-A) in Couples With Non-obstructive Azoospermia (NOA) | 2026-12 |
| NCT06841861CellARTs Inc.Spermatogonial Differentiation Via Testicular Organoid | 2026-12-01 |
| NCT05479474Stanford UniversityPlatelet Rich Plasma Testis Treatment for Infertile Men | 2026-12-31 |
| NCT05951075The Bird and Be Co IncProspective Study on Power Prenatal Vitamins for Males on YO Score At-home Sperm Test Results | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 58 studies in Infertility, Male with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study of infertility which often occurs in men with spinal cord injury. Most men with spinal cord injury have a normal sperm count but abnormally low sperm motility - which means that the sperm does not swim well. This study will determine if a medicine given by mouth will improve sperm motility in men with spinal cord injuries. The medicine is called probenecid.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive the full dose of probenecid for a total of 90 days.
Drug: Probenecid 500 Milligrams (mg)
Participants in this group will receive half the dose of probenecid for a total of 90 days.
Drug: probenecid 250 Milligrams (mg)
Participants in this group will receive a placebo dose (No active ingredient) for a total of 90 days.
Drug: Placebo
Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
Change in total motile sperm count
The total sperm count will be assessed by calculating semen volume times sperm count times sperm motility percentage.The unit of measurement is in Millions.
Time frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.
Change in percentage sperm DNA fragmentation
The percentage of DNA fragmented sperm in specimen
Time frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.
Change in percentage of sperm viability
The percentage of viable sperm ion specimen
Time frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.
Change in semen inflammasome markers
Markers will be measured in picogram/milliliter units
Time frame: Baseline, up to 6 months post intervention, up to 6 months post follow up.
Number of treatment-related adverse events
Treatment-related adverse events will be assessed by the treating physician using Common Terminology Criteria for Adverse Events 4 (CTCAE 4)
Time frame: Up to 6 months post follow up.
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for May 2027, 40 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.